Skip to main content
. 2023 Mar 11;14:1333. doi: 10.1038/s41467-023-36933-y

Fig. 5. cBioportal analysis reveals polygenic FANC tumor mutation combinations found in FA patients are associated with decreased survival in breast cancer patients.

Fig. 5

a Kaplan–Meier curves for overall survival of breast cancer patients with tumor mutations in both, BRCA2 and RAD51C (polygenic BRCA2 + RAD51C, n = 16, p = 0.00611), with mutations in either, BRCA2 and RAD51C genes (monogenic BRCA2 + RAD51C, n = 318, p = 0.224), or with no BRCA2/RAD51C tumor mutations (n = 2729). b Kaplan-Meier curves for overall survival of breast cancer patients with tumor mutations in combinations of FANC genes identified to be mutated in the same FA patients (16 pairs, FA patient polygenic FANC, n = 63, p = 0.009663), with mutations in one FANC gene (monogenic FANC, n = 923, p = 0.212), or with no FANC tumor mutations (n = 2077). c Kaplan–Meier curves for overall survival of breast cancer patients with tumor mutations in any combinations of FANC genes identified in FA patients (Any polygenic FANC, n = 623), with mutations in one FANC gene (monogenic FANC, n = 796), or with no FANC tumor mutations (n = 1644, p = 0.216). p-values for all survival curves are derived from cBioportal using the Log-Rank test.